Translational research in pancreatic ductal adenocarcinoma: Current evidence and future concepts

Table 1 Summary of current evidence on selected biomarkers in pancreatic ductal adenocarcinoma discussed in this topic highlight

Ref.	Biomarker	Prognostic	Predictive (for)	Dissemination pattern
Iacobuzio-Donahue et al[12]	SMAD4	N/A	N/A	+
Oshima et al[13]		+	N/A	+
Bachet et al[14]		-	+ (adjuvant chemotherapy)	-
Winter et al[15]		-	N/A	-
Bachet et al[14]	CXCR4	+	-	+
Maréchal et al[18]		+	N/A	+
Gebauer et al[19]		-	N/A	-
Lee et al[27]	KRAS	+	N/A	N/A
Shin et al[28]		+	N/A	N/A
Ogura et al[29]		+	N/A	N/A
Boeck et al[22,31]		+	? (erlotinib)	N/A
Kim et al[24]		-	+ (erlotinib)	N/A
da Cunha Santos et al[32]		-	-	N/A
Oliveira-Cunha et al[33]		-	N/A	N/A
Farrell et al[48]	hENT1	-	+ (adjuvant gemcitabine)	N/A
Morinaga et al[49]		-	+ (adjuvant gemcitabine)	N/A
Maréchal et al[50]		-	+ (adjuvant gemcitabine)	N/A
Greenhalf et al[52]		-	+ (adjuvant gemcitabine)	N/A
Jordheim et al[51]		-	+ (review on 18 studies on adjuvant gemcitabine)	N/A
Poplin et al[53]		-	- (gemcitabine in metastatic PDA)	N/A

(+): Results suggest that the respective molecule might serve as a biomarker; (-): No evidence found that the respective molecule might serve as a biomarker; (?): Unclear whether the respective molecule could serve as a biomarker. N/A: No data available; in cited study; PDA: Pancreatic ductal adenocarcinoma.